Five-year irish trial of CLI patients with TASC II type C/D lesions undergoing subintimal angioplasty or bypass surgery based on plaque echolucency

Journal of Endovascular Therapy

Volumn 16, Issue 3, 2009, Pages 270-283

  Sultan, Sherif ^a,b   Hynes, Niamh ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b Galway Clinic ^*  (Ireland)

Author keywords

Amputation; Bypass grafting; Complications; Cost effectiveness; Critical limb ischemia; Outcome analysis; Quality of life; Restenosis; Subintimal angioplasty

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; FIBRINOGEN; PRAVASTATIN;

ADULT; AGED; ANGIOPLASTY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BYPASS SURGERY; COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HOSPITALIZATION; HUMAN; IRELAND; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE PROCEDURE; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; Q TWIST; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESTENOSIS; REVASCULARIZATION; RUTHERFORD CLASSIFICATION; SUBINTIMAL ANGIOPLASTY; SURGICAL TECHNIQUE; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY; BLOOD VESSEL PROSTHESIS IMPLANTATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRELAND; ISCHEMIA; LEG; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 68649108207     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/08-2581.1     Document Type: Article

References (50)

1. Norgren L, Hiatt WR, Dormandy JA, et al. InterSociety Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-67. (Pubitemid 46068992)
2. Sultan S, Hynes N. Recent trends in the management of peripheral vascular disease in high risk patients. Diabetes Wise. 2006;3(2):15-19.
3. Hynes N, Sultan S. The influence of subintimal angioplasty on level of amputation and limb salvage rates in lower limb critical ischaemia: a 15-year experience. Eur J Vasc Endovasc Surg. 2005;30:291-299. (Pubitemid 41093535)
4. Fowkes F, Leng GC. Bypass surgery for chronic lower limb ischemia. Cochrane Database Syst Rev. 2008;(2):CD002000. (Pubitemid 351807257)
5. Sultan S, Hynes N. Recent trends in the management of peripheral vascular disease in high risk patients. Heart Wise. 2007;10(2):21-25.
6. Khan SM, Beard JD. Management of critical leg ischaemia and quality of life. In: Earnshaw JJ, Murie JA, eds. The Evidence for Vascular Surgery. Shropshire, UK: TFM Publishing Ltd; 2007:73-79.
7. Hynes N, Akhtar Y, Manning B, et al. Subintimal angioplasty as a primary modality in the management of critical limb ischemia: comparison to bypass grafting for aortoiliac and femoropopliteal occlusive disease. J Endovasc Ther. 2004;11:460-471. (Pubitemid 39096344)
8. Akesson M, Riva L, Ivancev K, et al. Subintimal angioplasty of infrainguinal arterial occlusions for critical limb ischemia: long-term patency and clinical efficacy. J Endovasc Ther. 2007;14:444-451. (Pubitemid 350154989)
9. Lazaris AM, Tsiamis AC, Fishwick G, et al. Clinical outcome of primary infrainguinal subintimal angioplasty in diabetic patients with critical lower limb ischemia. J Endovasc Ther. 2004;11:447-453. (Pubitemid 39096342)
10. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517-538. (Pubitemid 27408567)
11. Oaikhinan K, Sultan S. An observational parallel group comparative study with and without the "Magic Bullet" (MB: Aspirin, cardio selective beta-blocker, pravastatin and clopidogrel) in the peri-operative and postoperative period for abdominal aortic aneurysms surgery and femoral-popliteal segment revascularisation. Does the "Magic Bullet" improve the 30-day morbidity and mortality outcome? Br J Surg. 2004;91:113-114.
12. Diehm N, Baumgartner I, Jaff M, et al. A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries. Eur Heart J. 2007;28:798-805.
13. Gelber RD, Gelman RS, Goldhirsh A. A quality-of-life-orientated endpoint for comparing therapies. Biometrics. 1989;45:781-795.
14. Brothers TE, Robison JG, Elliott BM. Prospective decision analysis for peripheral vascular disease predicts future quality of life. J Vasc Surg. 2007;46:701-708.
15. Hynes N, Sultan S. A prospective clinical, economic, and quality-of-life analysis comparing endovascular aneurysm repair (EVAR), open repair, and best medical treatment in high-risk patients with abdominal aortic aneurysms suitable for EVAR: the Irish patient trial. J Endovasc Ther. 2007;14:763-776. (Pubitemid 350253094)
16. Lowery AJ, Hynes N, Sultan S. A prospective feasibility study of duplex ultrasound arterial mapping, digital-subtraction angiography, and magnetic resonance angiography in management of critical lower limb ischemia by endovascular revascularization. Ann Vasc Surg. 2007;21:443-451. (Pubitemid 47030835)
17. Marks NA, Ascher E, Hingorani AP, et al. Gray-scale median of the atherosclerotic plaque can predict success of lumen re-entry during subintimal femoral-popliteal angioplasty. J Vasc Surg. 2008;47:109-115.
18. Jämsén T, Manninen H, Tulla H, et al. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. J Vasc Interv Radiol. 2002;13:455-463. (Pubitemid 34526284)
19. Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg. 2005;41:423-435. (Pubitemid 40523584)
20. DeRubertis BG, Pierce M, Chaer RA, et al. Lesion severity and treatment complexity are associated with outcome after percutaneous infra-inguinal intervention. J Vasc Surg. 2007;46:709-716. (Pubitemid 47454692)
21. DeRubertis BG, Pierce M, Ryer EJ, et al. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb threatening ischemia. J Vasc Surg. 2008;47:101-108.
22. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909-1916.
23. Fryer RH, Wilson BD, Gubler DB, et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993;13:1327-1333.
24. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369-6373. (Pubitemid 24200662)
25. Heneghan HM, Sultan S. Homocysteine, the cholesterol of the 21st century. Impact of hyperhomocysteinemia on patency and amputation-free survival after intervention for critical limb ischemia. J Endovasc Ther. 2008;15:399-407.
26. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-1600. (Pubitemid 33126838)
27. Laxdal E, Wirsching J, Pedersen G, et al. Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the common iliac arteries. Eur J Vasc Endovasc Surg. 2006;31:244-250. (Pubitemid 43263504)
28. Herrmann W. Homocysteine research: alive and kicking. Clin Chem Lab Med. 2007;45:1571-1574.
29. Ihnat DM, Duong ST, Taylor ZC, et al. Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score. J Vasc Surg. 2008;47:967-974.
30. Tawfick W, Sultan S. Tibial balloon angioplasty (TBA) vs cool excimer laser assisted angioplasty (CELA) in management of infragenicular tibial arterial occlusion in critical lower limb ischaemia (CLI): an observational parallel group comparative study. J Cardiovasc Surg (Torino). 2008;49:S22-23.
31. Lazaris AM, Salas C, Tsiamis AC, et al. Factors affecting patency of subintimal infrainguinal angioplasty in patients with critical lower limb ischemia. Eur J Vasc Endovasc Surg. 2006;32:668-674. (Pubitemid 44661074)
32. Cejna M, Turnher S, Illiasch H, et al. PTA versus Palmaz stent in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23-31. (Pubitemid 32097991)
33. Grimm J, Muller-Hulsbeck S, Jahnke T, et al. Randomized study to compare PTA alone versus Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12:935-942. (Pubitemid 32756862)
34. Becquemin JP, Favre JP, Marzelle J, et al. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg. 2003;37:487-494. (Pubitemid 36350887)
35. Nishino M, Hoshida S, Kato H, et al. Preprocedural statin administration can reduce thrombotic reaction after stent implantation. Circ J. 2008;72:232-237.
36. Schillinger M, Exner M, Mlekusch W, et al. Fibrinogen predicts restenosis after endovascular treatment of the iliac arteries. Thromb Haemost. 2002;87:959-965. (Pubitemid 34624876)
37. Otsuka M, Hayashi Y, Ueda H, et al. Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis. 2002;164:371-378. (Pubitemid 35223089)
38. Jaster M, Horstkotte D, Willich T, et al. The amount of fibrinogen-positive platelets predicts the occurrence of in-stent restenosis. Atherosclerosis. 2008;197:190-196. (Pubitemid 351273237)
39. Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998;98:224-233. (Pubitemid 28337613)
40. Cutlip DE. Stent thrombosis: historical perspectives and current trends. J Thromb Thrombolysis. 2000;10:89-101.
41. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. Determinants of functional outcome after revascularization for critical limb ischemia: an analysis of 1000 consecutive vascular interventions. J Vasc Surg. 2006;44:747-756.
42. Goshima KR, Mill JL, Hughes JD. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. J Vasc Surg. 2004;39:330-335.
43. Chung J, Bartelson BB, Hiatt WR, et al. Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia. J Vasc Surg. 2006;43:1183-1190. (Pubitemid 43825661)
44. Nehler MR, McDermott MM, Treat-Jacobson D, et al. Functional outcomes and quality of life in peripheral arterial disease: current status. Vasc Med. 2003;8:115-126. (Pubitemid 37168253)
45. Landry GJ. Functional outcome of critical limb ischemia. J Vasc Surg. 2007;45 Suppl A:A141-8.
46. O'Brien-Irr MS, Harris LM, Dosluoglu HH, et al. Lower extremity endovascular interventions: can we improve cost-efficiency? J Vasc Surg. 2008;47:982-987.
47. Jansen RM, de Vries SO, Cullen KA, et al. Cost-identification analysis of revascularization procedures on patients with peripheral arterial occlusive disease. J Vasc Surg. 1998;28:617-623.
48. Janne d'Othée B, Langdon DR, Bell GK, et al. Operating expenses for the diagnosis and treatment of peripheral vascular disease in an academic interventional radiology department: cost calculations according to a microeconomic method. J Vasc Interv Radiol. 2006;17:85-94.
49. Janne d'Othée B, Morris MF, Powell RJ, et al. Cost determinants of percutaneous and surgical interventions for treatment of intermittent claudication from the perspective of the hospital. Cardiovasc Intervent Radiol. 2008;31:56-65.
50. Stoner MC, deFreitas DJ, Phade SV, et al. Mid-term results with laser atherectomy in the treatment of infrainguinal occlusive disease. J Vasc Surg. 2007;46:289-295.